Nicotine TransDermal Patch

On-going Transdermal Patch projects

The nicotine patch is a transdermal reservoir, which is designed to deliver 5 mg, 10 mg and 15 mg of the active ingredient Nicotine through the skin over 16 hours of administration. The 15mg/16hr.

EU-dossier was submitted to the UK MHRA and the marketing authorization is expected to be granted soon.

Other strengths of Nicotine patch under development are 24hr.

They are developed as doses of 7, 14, & 21mg.

Partnering opportunities are sought through Out-licensing, Co-development, Co-manufacturing, Marketing and Distribution, and other contractual manufacturing agreements.

Advantages:

• Bioequivalent to market leader Nicorette.
• Up to 50% Smaller than marketed products.
• Lower drug load
• Higher drug utilization with lower residual content
• Significantly less irritation to human skin.
• Lower unit costs.